Syantra is a precision healthcare company that commercializes the Syantra DX™ Breast Cancer test, a blood-based assay that analyzes gene expression biomarkers to detect early-stage breast cancer. This test addresses the limitations of traditional mammography, particularly for women with dense breast tissue, by providing a minimally invasive screening option with an inferred accuracy of 98.5% for women under 50.
Funding
$10.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AICGPATAFounders
Product
Problem
Traditional breast cancer screening methods, like mammography, can be less effective for women with dense breast tissue, leading to potential missed diagnoses or delayed detection. Current screening methods may also be invasive or uncomfortable, deterring some women from regular check-ups.
Solution
Syantra DX™ Breast Cancer is a blood-based screening test designed to detect early-stage breast cancer through the analysis of gene expression biomarkers. The test utilizes a machine learning-driven software package to interpret biomarker data from a whole blood sample, providing a positive or negative result. This minimally invasive approach offers a convenient and accurate alternative or complement to traditional screening methods, particularly beneficial for women with dense breast tissue and those under 50. By detecting cancer signals at the earliest stages, Syantra DX™ Breast Cancer aims to improve treatment outcomes and overall survival rates. The test has demonstrated high accuracy in clinical studies, offering a new tool for early breast cancer detection.
Target Audience
The primary target audience includes women aged 25-80, particularly those with dense breast tissue or who are under the recommended screening age for mammography, as well as healthcare providers seeking advanced screening tools.
Features
- Gene expression analysis of whole blood samples to identify breast cancer biomarkers.
- Machine learning algorithms for data interpretation and result generation.
- Minimally invasive blood draw procedure.
- High inferred accuracy (98.5%) for women under 50 in clinical studies.
- Ongoing international clinical studies (IDBC) to further validate test performance.
- CE mark approval for marketing in the European Union and other recognizing countries.